Table 1.
Demographic and clinical characteristics of each sample across stages
| Description | Stage 1 (N = 30) | Stage 2 (N = 30) | Stage 3 (N = 15) | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age (years) | Mean (Min, max) | 29.4 (12, 49) | 29.2 (12,49) | 32.5 (19, 45) |
| Length of time experiencing pelvic pain, years | Mean (Min–Max) | 8.7 (0.5–27) | 5.8 (1–16) | 7.13 (1- 27) |
| Race, n (%) | White | 14 (46.7%) | 14 (46.7%) | 9 (60.0%) |
| Black/African American | 12 (40.0%) | 9 (30.0%) | 3 (20.0%) | |
| Other | 4 (13.3%) | 7 (23.3%) | 1 (6.7%) | |
| North African or Alaska Native | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) | |
| Multi-Racial | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) | |
| Ethnicity, n (%) | Non-Hispanic or Latino | 18 (60.0%) | 21 (70.0%) | 9 (60.0%) |
| Hispanic or Latino | 12 (40.0) | 9 (30.0%) | 6 (40.0%) | |
| Highest level of education (adults only), n (%) | College or university degree | 7 (23.3%) | 6 (20.0%) | 2 (13.3%) |
| High school diploma or General Education Diploma | 7 (23.3%) | 4 (13.3%) | 4 (26.7%) | |
| Some years of college | 4 (13.3%) | 6 (20.0%) | 5 (33.3%) | |
| Certificate Program | 2 (6.7%) | 3 (10.0%) | 3 (20.0%) | |
| Graduate or professional degree | 0 (0.0%) | 1 (6.7%) | 1 (6.7%) | |
| Work status, n (%) | Working full or part time | 17 (56.7%) | 19 (63.3%) | 13 (86.7%) |
| At school or student | 10 (33.3%) | 9 (30.0%) | 1 (6.7%) | |
| Full time homemaker | 3 (10.0%) | 2 (6.7%) | 1 (6.7%) | |
| Clinical characteristics | ||||
| Time since diagnosis*, years | Less than 5 years | 15 (50%) | 21 (70.0%) | 8 (53.3%) |
| 6–10 years | 6 (20%) | 3 (10.0%) | 6 (40.0%) | |
| Over 10 years | 9 (30.0%) | 6 (20.0%) | 1 (6.7%) | |
| Type of chronic pelvic pain, n (%) | Cyclic pain only | 16 (53.3%) | 19 (63.3%) | 9 (60.0%) |
| Cyclic and non-cyclic pain | 14 (46.7%) | 11 (36.7%) | 6 (40.0%) | |
| Severity of cyclic (menstrual) pelvic pain at screening using 0–10 Numerical Rating Scale (NRS)***, n (%) | Mild (1–4) | 7 (23.3%) | 6 (20.0%) | 5 (33.3%) |
| Moderate (5–7) | 12 (40.0%) | 9 (30.0%) | 5 (33.3%) | |
| Severe (8–10) | 11 (36.7%) | 15 (50.0%) | 5 (33.3%) | |
| Mean (range) | 6.53 (3–10) | 7.27 (3–10) | 6.07 (2–10) | |
| Severity of non-cyclic (non-menstrual) pelvic pain at screening using 0–10 NRS***, n (%) | Mild (1–4) | 10 (33.3%) | 12 (40.0%) | 4 (26.7%) |
| Moderate (5–7) | 13 (43.3%) | 9 (30.0%) | 7 (46.7%) | |
| Severe (8–10) | 7 (23.3%) | 9 (30.0%) | 4 (26.7%) | |
| Mean (range) | 5.6 (3–10) | 6.13 (3–10) | 5.87 (2–10) | |
| Diagnostic procedure, n (%) | Surgical diagnosis | 30 (100%) | 20 (66.7%) | 15 (100%) |
| Clinically suspected endometriosis | 0 (0.0%) | 10 (33.3%) | 0 (0.0%) | |
| Hormonal therapy, n (%) | On hormonal therapy | 15 (50.0%) | 15 (50.0%) | 9 (60.0%) |
| Not on hormonal therapy | 15 (50.0%) | 15 (50.0%) | 6 (40.0%) | |
| Current treatment**, pharmacological (non-hormonal), n (%) | Nonsteroidal Anti-Inflammatory Drugs | 25 (83.3%) | 24 (80.0%) | 12 (80.0%) |
| Other pain medications (incl. Acetaminophen) | 2 (6.7%) | 15 (50.0%) | 4 (26.7%) | |
| Opiate (incl. codeine, oxycodone) | 3 (10%) | 3 (10.0%) | 1 (6.7%) | |
*This has been calculated from date of interview
**More than one current/previous treatment was reported for some participants
***The following interpretative pain severity cut-offs were employed for the 0–10 NRS: 1–4 was considered Mild, 5–7 was considered Moderate, and 8–10 was considered Severe